Immune-mediated conditions, including hypophysitis, isolated adrenocorticotropic hormone deficiency, renal injury, and thyroiditis, are frequently reported during PD-1/PD-L1 inhibitor treatment (12, 53, 54). Here, PDCD1 is linked to thyroid gland disorder.